FMP
Nanobiotix S.A.
NBTX
NASDAQ
Nanobiotix S.A., a clinical-stage biotechnology, focuses on developing product candidates for the treatment of cancer. Its lead product candidate is NBTXR3, a sterile aqueous suspension of crystalline hafnium oxide nanoparticles used for the treatment of soft tissue sarcoma, head and neck cancers, liver cancers, prostate cancer, pancreatic cancer, esophageal cancer, rectal cancer, and non-small cell lung cancer. Nanobiotix S.A. has a partnership with LianBio to develop and commercialize NBTXR3 in Greater China, South Korea, Singapore, and Thailand. The company was incorporated in 2003 and is headquartered in Paris, France.
3.34 USD
0.031 (0.928%)
Balance Sheet
Year
2020
2021
2022
2023
2024
2025
2026
2027
2028
2029
Total Cash
135.58M
95.49M
47.1M
85.67M
56.6M
-8.32M
-8.74M
-9.18M
-9.63M
-10.12M
Total Cash %
238.3k
839.21k
866.58
207.92
-428.43
60
60
60
60
Receivables
4.42M
7.88M
114.93k
3.38M
9.71M
-3.79M
-3.98M
-4.18M
-4.39M
-4.61M
Receivables %
7.76k
69.26k
2.11
8.19
-73.52
27.36
27.36
27.36
27.36
Inventories
-45.88M
-3.46M
3.39M
227.58k
-
3.8M
3.99M
4.19M
4.4M
4.62M
Inventories %
-80.64k
-30.43k
62.42
0.55
-
-27.41
-27.41
-27.41
-27.41
Payable
6.34M
5.69M
4.55M
7.62M
5.1M
-7.31M
-7.68M
-8.06M
-8.47M
-8.89M
Payable %
11.15k
49.96k
83.73
18.49
-38.63
52.72
52.72
52.72
52.72
Cap Ex
-121.76k
-265.13k
-105.83k
-383.48k
-964.95k
5.63M
5.91M
6.2M
6.52M
6.84M
Cap Ex %
-214
-2.33k
-1.95
-0.93
7.3
-40.58
-40.58
-40.58
-40.58
